NCT05321251 is a Phase 2, PHASE3 clinical trial of Insulin in Neurotrophic Keratitis, sponsored by University of Alberta.

Who is sponsoring NCT05321251?

NCT05321251 is sponsored by University of Alberta.

What drugs are being tested in NCT05321251?

Interventions in NCT05321251: Insulin, Tarsorrhaphy.

What condition does NCT05321251 study?

NCT05321251 studies Neurotrophic Keratitis.

Is NCT05321251 still recruiting?

NCT05321251 is currently withdrawn. Last updated 5 February 2024.

Last reviewed 2024-02-05 · How we verify

NCT05321251

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.

Withdrawn Phase 2, PHASE3 Last updated 5 February 2024

What this trial tests

Phase 2, PHASE3 trial testing Insulin in Neurotrophic Keratitis. Withdrawn.

Timeline

1 June 2022

Primary endpoint
18 October 2023

18 October 2023

Quick facts

Lead sponsor	University of Alberta
Phase	Phase 2, PHASE3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 June 2022
Primary completion	18 October 2023
Estimated completion	18 October 2023
Sites	6 locations across Canada

Drugs / interventions tested

Insulin (insulin) — full drug profile →
Tarsorrhaphy

Conditions studied

Neurotrophic Keratitis — all drugs for Neurotrophic Keratitis →

Sponsor

University of Alberta

Who can join

18 and older, any sex, with Neurotrophic Keratitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many diseases can affect corneal nerves. Corneas that lack normal sensation are considered neurotrophic. Neurotrophic corneas are predisposed to persistent epithelial defects, recurrent erosions, and corneal ulcers. These can lead to a variety of complications, from subjective pain, discomfort, and blurry vision, to corneal perforation and endophthalmitis. Neurotrophic corneas and the persistent epithelial defects associated with them can be very difficult to treat. Non-invasive measures include topical drops (artificial tears, antibiotics, or steroids), bandage contact lens, and punctal plugs. More invasive surgical treatments include membrane grafts, tarsorrhaphy, and keratoplasty. Despite these treatments, many neurotrophic corneas still do not heal. This study aims to test the efficacy of topical insulin in the treatment of neurotrophic keratopathy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease.
Valdés-Arias D, Locatelli EVT, Sepulveda-Beltran PA, Mangwani-Mordani S, et al · · 2024 · cited 16× · PMID 38652355 · DOI 10.1007/s40265-024-02031-6

Verify or expand the search:

Other trials of Insulin

Trials testing the same drug.

NCT07460336 — Effects of Cofrogliptin on Beta-Cell Function in LADA Patients · NA · not yet recruiting
NCT07259564 — A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) · Phase 2 · not yet recruiting
NCT06762314 — Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes · Phase 2 · recruiting
NCT06781775 — GDM: Insulin with or Without Metformin? · Phase 4 · recruiting
NCT06391853 — Investigating Brain Insulin Resistance in Alzheimer Disease with IntraNasal Insulin : a Multimodal Neuroimaging Study · NA · withdrawn

Other recruiting trials for Neurotrophic Keratitis

Currently open trials in the same condition.

NCT06964269 — Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune D · Phase 4 · recruiting
NCT05927428 — Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic Keratitis · Phase 2 · recruiting
NCT06947850 — DOMPE -MT Neurotrophic Keratitis · Phase 4 · active not recruiting
NCT04573647 — OCT Evaluation of Neurotrophic Ulcer Following Treatment With Oxervate · recruiting

Other University of Alberta trials

Trials by the same sponsor.

NCT03240900 — Electrical Stimulation for Improving Postoperative Breast Sensation · NA · not yet recruiting
NCT04231760 — The Effect of Inhaled Nitric Oxide on Pulmonary Gas-exchange in COPD · Phase 1, PHASE2 · not yet recruiting
NCT06649604 — Reducing Pain From Retinal Laser With Vibrational Stimulation · NA · not yet recruiting
NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT06920914 — Effects of Minimally vs. Ultra-Processed Diets on Potassium (K) Handling in CKD · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05321251 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alberta
Last refreshed: 5 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05321251.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing